In this study, we showed that circulating MDMs in plasma are highly complementary to CEA and can detect recurrent CRC in patients after receiving definitive treatment preceding radiographic evidence and can discern patients’ treatment response to anticancer therapies. This evidence concerns the gene CEACAM5 and colorectal carcinoma.